Trial · NCT03725202
Participant flow64
How many started, completed or left each group, period by period.
1 to 20 of 64
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Period 1 (Baseline - Week 52) | STARTED | Placebo + 52-week CS Taper | 112 | |
| Period 1 (Baseline - Week 52) | STARTED | 7.5 mg Upadacitinib + 26-week CS Taper | 107 | |
| Period 1 (Baseline - Week 52) | STARTED | 15 mg Upadacitinib + 26-week CS Taper | 210 | |
| Period 1 (Baseline - Week 52) | STARTED | Placebo + 52-week CS Taper -> Placebo | 0 | |
| Period 1 (Baseline - Week 52) | STARTED | 7.5 mg Upadacitinib + 26-week CS Taper -> 7.5 mg Upadacitinib | 0 | |
| Period 1 (Baseline - Week 52) | STARTED | 7.5 mg Upadacitinib + 26-week CS Taper -> Placebo | 0 | |
| Period 1 (Baseline - Week 52) | STARTED | 15 mg Upadacitinib + 26-week CS Taper -> 15 mg Upadacitinib | 0 | |
| Period 1 (Baseline - Week 52) | STARTED | 15 mg Upadacitinib + 26-week CS Taper -> Placebo | 0 | |
| Period 1 (Baseline - Week 52) | Randomized | Placebo + 52-week CS Taper | 112 | |
| Period 1 (Baseline - Week 52) | Randomized | 7.5 mg Upadacitinib + 26-week CS Taper | 107 | |
| Period 1 (Baseline - Week 52) | Randomized | 15 mg Upadacitinib + 26-week CS Taper | 210 | |
| Period 1 (Baseline - Week 52) | Randomized | Placebo + 52-week CS Taper -> Placebo | 0 | |
| Period 1 (Baseline - Week 52) | Randomized | 7.5 mg Upadacitinib + 26-week CS Taper -> 7.5 mg Upadacitinib | 0 | |
| Period 1 (Baseline - Week 52) | Randomized | 7.5 mg Upadacitinib + 26-week CS Taper -> Placebo | 0 | |
| Period 1 (Baseline - Week 52) | Randomized | 15 mg Upadacitinib + 26-week CS Taper -> 15 mg Upadacitinib | 0 | |
| Period 1 (Baseline - Week 52) | Randomized | 15 mg Upadacitinib + 26-week CS Taper -> Placebo | 0 | |
| Period 1 (Baseline - Week 52) | Received Randomized Study Drug | Placebo + 52-week CS Taper | 112 | |
| Period 1 (Baseline - Week 52) | Received Randomized Study Drug | 7.5 mg Upadacitinib + 26-week CS Taper | 107 | |
| Period 1 (Baseline - Week 52) | Received Randomized Study Drug | 15 mg Upadacitinib + 26-week CS Taper | 209 | |
| Period 1 (Baseline - Week 52) | Received Randomized Study Drug | Placebo + 52-week CS Taper -> Placebo | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03725202/flow